Reddell, Paul
QBiotics Group Limited , Yungaburra, Queensland,
3 papers on CoChatORCID 0000-0002-0993-8957
Most cited papers
- Verified
Intra-Lesional Injection of the Novel PKC Activator EBC-46 Rapidly Ablates Tumors in Mouse Models
Boyle, G. M., D'Souza, M. M. A., Pierce, C. J., Adams, R. A., Cantor, A. S., Johns, J. P., Maslovskaya, L., Gordon, V. A., Reddell, P. W., & Parsons, P. G. (2014) · PLoS ONE
Nonmelanoma Skin Cancer StudiesImmunotherapy and Immune Responses
Cited by 101
- Verified
Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC‐46)
De Ridder, T. R., Campbell, J. E., Burke-Schwarz, C., Clegg, D., Elliot, E. L., Geller, S., Kozak, W., Pittenger, S. T., Pruitt, J. B., Riehl, J., et al. (2021) · Journal of Veterinary Internal Medicine
Veterinary Oncology ResearchVeterinary Medicine and Surgery
Cited by 81
- Verified
Dose Characterization of the Investigational Anticancer Drug Tigilanol Tiglate (EBC‐46) in the Local Treatment of Canine Mast Cell Tumors
Miller, J., Campbell, J., Blum, A., Reddell, P., Gordon, V., Schmidt, P., & Lowden, S. (2019) · Frontiers in Veterinary Science
Veterinary Oncology ResearchVeterinary Pharmacology and Anesthesia
Cited by 50
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free